Navigation Links
JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
Date:8/24/2009

Manipulating the functions of melanosomes--the organelles in pigment-producing cells--may enhance the activity of anticancer drugs used against melanoma, according to a new study published online August 24 in the Journal of the National Cancer Institute.

To examine the role of melanosomes in the sensitivity of malignant melanoma to chemotherapeutic agents, Kevin Chen, Ph.D., Vincent Hearing, Ph.D., Michael M. Gottesman, M.D., of the Laboratory of Cell Biology at the National Cancer Institute in Bethesda, Md., and colleagues compared pigmentation and melanosome developmental stage, number, and cellular structures in melanoma cell lines in response to treatment with chemotherapeutic agents.

The authors found that late-stage melanosomes that were damaged and thus could not trap metabolites were toxic to melanoma cells. They also found that melanoma cells that survived cisplatin treatment had more stage II-III functional melanosomesalso known as early melansomes because they have not initiated melanin synthesisthan untreated melanoma cells. In addition, when melanosomes were reverted to relatively early stages, the melanoma cells became more resistant to cisplatin.

"We believe that manipulation of melanosome status either by cytotoxic or by noncytotoxic drugs opens therapeutic avenues and raises the prospect of successfully treating pigment-producing cell-related diseases and, in particular, highly intractable malignant melanomas," the authors write.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
2. JNCI news brief: High serum insulin levels and risk of prostate cancer
3. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
6. JNCI news brief: Improving the biomarker pipeline for early cancer detection
7. In brief: New prognostic indicator for patients with IPF
8. MicroDynamics to Introduce New Microscope at Quality Expo
9. CardioDynamics Shareholders Approve Merger Agreement with SonoSite
10. CardioDynamics Reports Second Fiscal Quarter 2009 Results
11. General Dynamics Awarded $9 Million Contract for U.S. Army Medical Command Lean Six Sigma Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology: